You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 146 No. 11, November 1986 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Cephalosporin Therapy for Salmonellosis

Questions of Efficacy and Cross Resistance With Ampicillin

Charles E. Cherubin, MD; Robert H. K. Eng, MD; Sharon M. Smith, PhD; Ellie J. C. Goldstein, MD

Arch Intern Med. 1986;146(11):2149-2152.


Abstract



• The new cephalosporins should be explored for Salmonella septicemia efficacy, because of multiple-drug resistance, the high incidence of patient allergies to ampicillin and sulfamethoxazole-trimethoprim, and the limited number of antibiotics with proven efficacy. This study reports on six widely used cephalosporins: cephalothin, cefamandole, cefoperazone, cefoxitin, cefotaxime, and ceftriaxone with respect to in vitro killing of Salmonella. This in vitro activity was related to the stability of the agents to β-lactamases. Cefoperazone was the least stable, followed by cefamandole and cephalothin. Cefoxitin, cefotaxime, and ceftriaxone were the most stable. The β-lactamase—unstable agents permitted regrowth of β-lactamase—producing salmonella within 36 hours. Standard susceptibility tests showed good inhibitory levels by these unstable agents at 18 hours, but the minimum inhibitory concentrations increased dramatically with longer incubation periods. Based on these results, past cephalothin failures for ampicillin-resistant Salmonella can be explained. Additionally, there should be a dichotomy of effectiveness in the new cephalosporins depending on their β-lactamase stability. The stable cephalosporins deserve further clinical trials In the treatment of β-lactamase—producing Salmonella infections.

(Arch Intern Med 1986;146:2149-2152)



Author Affiliations



From the Department of Medicine, Bayley Seton Hospital, Staten Island, NY (Dr Cherubin), the Infectious Disease Section, Medical Service Microbiology Section, Laboratory Service, Veterans Administration Medical Center, East Orange, NJ (Dr Eng), and R. M. Alden Laboratory, Los Angeles (Drs Smith and Goldstein).


Footnotes



Accepted for publication March 3, 1986.

Reprint requests to Medical Service-111, Veterans Administration Medical Center, East Orange, NJ 07019 (Dr Eng).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Emergence of Domestically Acquired Ceftriaxone-Resistant Salmonella Infections Associated With AmpC {beta}-Lactamase
Dunne et al.
JAMA 2000;284:3151-3156.
ABSTRACT | FULL TEXT  

Salmonella Vertebral Osteomyelitis Treated With Cefotaxime
Dolan et al.
Arch Intern Med 1987;147:1667-1668.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.